Advanced Search
Contact | Corporate | Help

Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma

Sponsors:
  • M.D. Anderson Cancer Center
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • Transitional Cell Carcinoma
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Erlotinib Hydrochloride
Enrollment:
42

Additional information about NCT00749892.


SourceSolution © 2008-2012